At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 478 enrolled
Drug / intervention
Tirzepatide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Three Tirzepatide Doses Versus Placebo in Patients With Type 2 Diabetes, Inadequately Controlled With Diet and Exercise Alone
In Brief
A Phase 3 clinical trial evaluating Tirzepatide and Placebo for Type 2 Diabetes Mellitus. Completed, enrolled 478 participants across 53 sites in 5 countries.
Detailed Summary
The goal for this study is to evaluate the efficacy and safety of tirzepatide versus placebo in participants with type 2 diabetes not under control with diet and exercise alone. The study will last approximately 47 weeks and may include about 15 visits.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesIndia, Japan, Mexico, Puerto Rico, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
First PostedMay 2019
Enrollment StartJun 2019
Primary CompletionOct 2020
Study CompletionOct 2020
TodayJul 2026
First PostedMay 17, 2019
Enrollment StartJun 3, 2019
Primary CompletionOct 5, 2020
Study CompletionOct 28, 2020
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 7.1 years ago
Interventions
Tirzepatidedrug
Administered SC
Placebodrug
Administered SC